Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CHAT | P28329 | 4/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610868 | 0.98 | ALDH1A1 (0.42) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL669216 | 0.96 | ALDH1A1 (0.40) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| Methane SCHEMBL11666193 | 0.96 | ALDH1A1 (0.40) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL26063785 | 0.74 | ESR1 (0.38) | ALDH1A1 | |
| SCHEMBL27369540 | 0.72 | ALDH1A1 (0.48) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL4659202 | 0.71 | ALDH1A1 (0.37) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL31612244 | 0.71 | ALDH1A1 (0.37) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL11535969 | 0.69 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL7822399 | 0.69 | ALDH1A1 (0.36) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 | |
| SCHEMBL9232381 | 0.69 | POLB (0.38) | ALDH1A1HSD17B10CYP2A6TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103446-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4019501-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12503447-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-23 | — | — | US | disclosed |
| US-12391654-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250109113-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-03 | — | — | US | disclosed |
| US-12065412-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4071140-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20230357170-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-09 | — | — | US | disclosed |
| CN-115710233-A | Modulators of CFTR and methods of use thereof | 加利福尼亚大学董事会 | 2023-02-24 | — | — | CN | disclosed |
| EP-4071140-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | The Regents of The University of California (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2017112950-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112951-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-29 | — | — | WO | disclosed |
| US-9120768-B2 | Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing | THE HOSPITAL FOR SICK CHILDREN (CA) | 2015-09-01 | — | — | US | disclosed |
| US-20130150422-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS AND DISEASES ASSOCIATED WITH ABERRANT PROTEIN CELLULAR PROCESSING | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-06-13 | — | — | US | disclosed |
| WO-2012021974-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS AND DISEASES ASSOCIATED WITH ABERRANT PROTEIN CELLULAR PROCESSING | THE HOSPITAL FOR SICK CHILDREN (CA) | 2012-02-23 | — | — | WO | disclosed |
| US-20060014940-A1 | Cloning and characterization of slc26a6, slc26a1, and slc26a2 anion exchangers | MOUNT DAVID B | 2006-01-19 | — | — | US | disclosed |
| US-20050176945-A1 | Cloning and characterization of slc26a7 and slc26a9 anion exchangers | MOUNT JR DAVID B (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2003074664-A2 | CLONING AND CHARACTERIZATION OF SLC26A7 AND SLC26A9 ANION EXCHANGERS | VANDERBILT UNIVERSITY (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003072756-A2 | CLONING AND CHARACTERIZATION OF SLC26A8 AND SLC26A11 ANION EXCHANGERS | VANDERBILT UNIVERSITY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072759-A2 | CLONING AND CHARACTERIZATION OF SLC26A6, SLC26A1, AND SLC26A2 ANION EXCHANGERS | VANDERBILT UNIVERSITY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150422-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS AND DISEASES ASSOCIATED WITH ABERRANT PROTEIN CELLULAR PROCESSING | CFTR, PTMS, CHAMP1 | ALDH1A1 3291/4885HSD17B10 1396/4885CYP2A6 3005/4885 |
| US-12065412-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | ALDH1A1 2135/4885HSD17B10 2372/4885CYP2A6 1317/4885 |
| US-20230357170-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | ALDH1A1 2135/4885HSD17B10 2372/4885CYP2A6 1317/4885 |
| US-12391654-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | ALDH1A1 2135/4885HSD17B10 2372/4885CYP2A6 1317/4885 |
| US-20260103446-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, CLCN2, SLC26A3 | ALDH1A1 1179/4885HSD17B10 3094/4885CYP2A6 1013/4885 |
| US-12503447-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | ALDH1A1 2135/4885HSD17B10 2372/4885CYP2A6 1317/4885 |
| US-20250109113-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | ALDH1A1 2135/4885HSD17B10 2372/4885CYP2A6 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.